FDA Oncology Announcements

Announcements Trials

Anti-RANKL × Sarcoma × Clear all

Conditions

Breast 1 Genitourinary 1 Plasma cell 1 Sarcoma 1

Drug Classes

Anti-PD-1 4 PDGFR inhibitor 4 Bcr-Abl inhibitor 3 Anti-PD-L1 2 EZH inhibitor 2 Immunomodulatory drugs (IMiDs) 2 TRK inhibitor 2 ALK inhibitor 1 Alkylating agent 1 Anthracycline 1 Anti-HER2 ADC 1 Anti-MAGE-A4 SPEAR T-cell 1 Anti-PDGFR 1 Anti-RANKL 1 BRAF inhibitor 1 CSF1R inhibitor 1 Gamma secretase inhibitor 1 MEK inhibitor 1 MTOR inhibitor 1 Multikinase inhibitor 1 Non-taxane microtubule dynamics inhibitor 1 RET inhibitor 1 ROS1 inhibitor 1 VEGFR inhibitor 1

1 Announcement

FDA Approves Denosumab

Drug: Xgeva (denosumab) · Anti-RANKL antibody
Condition: Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡